Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...

In celebration of fathers, the Balm of Gilead Alternative Clinic, in collaboration with the New Tafo PIWC, held the second edition of the Legacy Fathers’ Awards to honour servicemen in Kumasi. The ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...